Objectives: In 2012, theCenters for Disease Control and Prevention initiated a national anti-smoking campaign, (). As a result of the campaign, quit attempts among smokers increased in the general population by 3.7 percentage points. In the current study, we assessed the effects of on smoking cessation in pregnant women.
Methods: We used 2009-2013 certificates of live births in three US states: Indiana, Kentucky and Ohio. Smoking cessation by the third trimester of pregnancy was examined among women who smoked in the 3 months prepregnancy. Campaign exposure was defined as overlap between the airing of 2012 (March 19-June 10) and the prepregnancy and pregnancy periods. Women who delivered before 2012 were not exposed. Adjusted logistic regression was used to determine whether exposure to was independently associated with smoking cessation.
Results: Cessation rates were stable during 2009-2011 but increased at the time 2012 aired and remained elevated. Overall, 32.9% of unexposed and 34.7% of exposed smokers quit by the third trimester (p<0.001). Exposure to 2012 was associated with increased cessation (adjusted OR: 1.07, 95% CI 1.05 to 1.10).
Conclusions: Exposure to a national anti-smoking campaign for a general audience was associated with smoking cessation in pregnant women.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778314 | PMC |
http://dx.doi.org/10.1136/bmjopen-2017-016826 | DOI Listing |
Asia Pac J Public Health
January 2025
Department of Dental Hygiene, College of Software and Digital Healthcare Convergence, Yonsei University, Wonju, South Korea.
This study evaluates the influence of smoking cessation policies and COVID-19 on the prevalence of smoking among Korean adolescents from 2011 to 2020. Based on the Korea Youth Risk Behavior Web-based Survey, trends in adolescent smoking behaviors were examined, including the impact of cigarette price increases, Pictorial Warning Labels (PWLs), and the onset of COVID-19. We used joinpoint regression analysis to discern annual changes in the prevalence of adolescent smokers.
View Article and Find Full Text PDFBMC Psychiatry
January 2025
Department of Behavioural Science and Health, University College London, London, 1-19 Torrington Place, WC1E 7HB, UK.
Background: Smoking rates in the UK have declined steadily over the past decades, masking considerable inequalities, as little change has been observed among people with a mental health condition. This trial sought to assess the feasibility and acceptability of supplying an electronic cigarette (e-cigarette) starter kit for smoking cessation as an adjunct to usual care for smoking cessation, to smokers with a mental health condition treated in the community, to inform a future effectiveness trial.
Methods: This randomised controlled feasibility trial, conducted March-December 2022, compared the intervention (e-cigarette starter kit with a corresponding information leaflet and demonstration with Very Brief Advice) with a 'usual care' control at 1-month follow-up.
J Gen Intern Med
January 2025
University of Connecticut School of Medicine, Farmington, CT, USA.
NPJ Parkinsons Dis
January 2025
Department of Neuroscience & Experimental Therapeutics, Texas A&M University College of Medicine, 8447 John Sharp Pkwy, Bryan, TX, 77807-3260, USA.
The smoking cessation drug cytisine exerts neuroprotection in substantia nigra pars compacta (SNc) dopaminergic (DA) neurons of female but not male 6-hydroxydopamine (6-OHDA) lesioned parkinsonian mice. To address the important question of whether circulating 17β-estradiol mediates this effect, we employ two mouse models aimed at depleting systemically circulating 17β-estradiol: (i) bilateral ovariectomy (OVX), and (ii) aromatase inhibition with systemically administered letrozole. In both models, depleting systemically circulating 17β-estradiol in female 6-OHDA lesioned parkinsonian mice results in the loss of cytisine-mediated neuroprotection as measured using apomorphine-induced contralateral rotations and SNc DA neurodegeneration.
View Article and Find Full Text PDFTob Control
January 2025
Retired, University of California San Francisco, San Francisco, California, USA.
In 2024, Philip Morris International's (PMI) website stated they support 'independent' continuing medical education courses on harm reduction for medical and other healthcare professionals. These courses mirrored industry marketing and political strategies by presenting smokeless tobacco products and e-cigarettes as alternatives to smoking, sometimes without mentioning tobacco cessation. The enactment of the US Family Smoking and Tobacco Control Act gave the US Food and Drug Agency jurisdiction over tobacco products and included the industry's 'continuum of risk' frame, and emboldened tobacco companies to make harm reduction claims about these products, which they had previously avoided for fear of triggering restrictive regulation of cigarettes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!